Methods for treating fibroproliferative disorders in a mammal
AssigneeThe Hospital for Special Children
InventorsBenjamin A. Alman, Raymond Poon, Helen Hong, Gene Gauzer
Life of this patent
Estimating the term…
Abstract
A topical drug composition for treating a β-catenin-mediated disorder in a mammal is provided comprising a Nefopam compound selected from Nefopam, or a functionally equivalent analogue, prodrug, salt or solvate thereof.
Claims14
1-24. (canceled)
A method of treating a fibroproliferative disorder in a mammal, comprising administering a Nefopam compound selected from Nefopam, or a functionally equivalent salt or solvate thereof, to the mammal.
A method of decreasing β-catenin levels in human fibroblast cells of a human subject having a fibroproliferative disorder comprising administering to the human subject an effective amount of Nefopam or a pharmaceutically acceptable salt or solvate thereof, wherein the fibroproliferative disorder comprises lung fibrosis, and wherein β-catenin levels in the human fibroblast cells are decreased.
A method of decreasing β-catenin levels in human fibroblast cells of a human subject having a fibroproliferative disorder comprising administering to the human subject an effective amount of Nefopam or a pharmaceutically acceptable salt or solvate thereof, wherein the fibroproliferative disorder comprises neurofibromatosis, and wherein β-catenin levels in the human fibroblast cells are decreased.
Dependencies are inferred from the claim text.